ERASCA INC
ERASNASDAQTrading Snapshot
- Day Range
- $14.59 – $15.32
- 52-Week Range
- $2.11 – $24.28
- Volume (shares)
- 3,391,417
- Avg Volume (shares)
- —
- Shares Outstanding
- 349.8M
- Next Earnings
- 2026-11-11
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-0.95
- Dividend Yield
- —
- Dilution (1yr)
- +0.2%
ERASCA INC
ERAS
StockOtter · stockotter.spaceAbout ERASCA INC
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
ⓘLatest News & Updates
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Erasca, Inc. - ERAS
NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ: ERAS). Such investors are advised to contact Danielle Peyton a
ERAS Investors with $100,000 in Losses Have Opportunity to Join Erasca, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $ERAS--ERAS Investors with $100,000 in Losses Have Opportunity to Join Erasca, Inc. Fraud Investigation with SBS Law.
Erasca (NASDAQ:ERAS) Shares Down 5.8% – What’s Next?
Shares of Erasca, Inc. (NASDAQ: ERAS - Get Free Report) fell 5.8% on Friday. The stock traded as low as $13.86 and last traded at $14.0050. Approximately 228,699 shares changed hands during mid-day trading, a decline of
Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); Erasca, Inc. (NASDAQ: ERAS); and Power Solutions International, Inc. (NASDAQ: PSIX): Grabar Law Office is Investigating Claims on Your Behalf
PHILADELPHIA, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (NASDAQ: AARD): Grabar Law Office is investigating claims on behalf of Aardvark Therapeutics, Inc. (NASDAQ: AARD) shareholders who purchased sha
Erasca: Revolution's Approval Just Took Risk Out Of The Fast Follower
Erasca (ERAS) is now a fully funded fast follower in RAS-targeted oncology, with ~$1B pro forma liquidity and three potential registration-enabling trials ahead. Daraxonrasib's FDA approval validates the RAS mechanism, s
Erasca, Inc. (NASDAQ:ERAS) Stock Has Consensus Target Price of $22.09
Erasca, Inc. (NASDAQ: ERAS - Get Free Report) has received an average recommendation of "Moderate Buy" from the eleven brokerages that are currently covering the stock, MarketBeat reports. One research analyst has rated